Comprehensive survey of HRAS, KRAS, NRAS mutations in proliferative thyroid lesions from an ethnically diverse population

Anticancer Research

Volumn 33, Issue 11, 2013, Pages 4779-4784

  Schulten, Hans Juergen ^a   Salama, Sherine ^a   Al Ahmadi, Alaa ^a   Al Mansouri, Zuhoor ^b   Mirza, Zeenat ^a   Al Ghamdi, Khalid ^c   Al Hamour, Osman Abdel ^b   Huwait, Etimad ^a   Gari, Mamdooh ^a   Al Qahtani, Mohammad Hussain ^a   Al Maghrabi, Jaudah ^a,b  

^a KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^b KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

^c King Abdulaziz University   (Saudi Arabia)

Author keywords

BRAF mutations; Follicular patterned thyroid lesions; HRAS; KRAS; KRAS codon 59 deletion; NRAS mutations

Indexed keywords

B RAF KINASE; K RAS PROTEIN; SELUMETINIB;

ARTICLE; CANCER SIZE; CODON; ETHNIC DIFFERENCE; FOLLICULAR ADENOMA; GENE MUTATION; GENE SEQUENCE; HASHIMOTO DISEASE; MUTATIONAL ANALYSIS; NODULAR GOITER; ONCOGENE H RAS; ONCOGENE K RAS; ONCOGENE N RAS; PAPILLARY THYROID MICROCARCINOMA; PRIORITY JOURNAL; PROTEIN STRUCTURE; THYROID CARCINOMA; THYROID DISEASE; THYROID HYPERPLASIA; THYROID PARAFOLLICULAR CELL;

BRAF MUTATIONS; FOLLICULAR-PATTERNED THYROID LESIONS; HRAS, KRAS AND NRAS MUTATIONS; KRAS CODON 59 DELETION;

ADENOMA; ADULT; CARCINOMA, PAPILLARY; DNA; ETHNIC GROUPS; FEMALE; FOLLOW-UP STUDIES; GOITER, NODULAR; GTP PHOSPHOHYDROLASES; HASHIMOTO DISEASE; HUMANS; MALE; MEMBRANE PROTEINS; MUTATION; NEOPLASM STAGING; POLYMERASE CHAIN REACTION; PROGNOSIS; PROTO-ONCOGENE PROTEINS P21(RAS); THYROID NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; WORLD HEALTH;

EID: 84891365202     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Bounacer A, McGregor A, Skinner J, Bond J, Poghosyan Z and Wynford-Thomas D: Mutant RAS-induced proliferation of human thyroid epithelial cells requires three effector pathways. Oncogene 23: 7839-7845, 2004.
2. Miller MS and Miller LD: RAS Mutations and oncogenesis: Not all RAS mutations are created equally. Front Genet 2: 100, 2011.
3. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Montalto G, Cervello M, Nicoletti F, Fagone P, Malaponte G, Mazzarino MC, Candido S, Libra M, Basecke J, Mijatovic S, Maksimovic-Ivanic D, Milella M, Tafuri A, Cocco L, Evangelisti C, Chiarini F and Martelli AM: Mutations and deregulation of RAS/RAF/MEK/ERK and PI3K/PTEN/AKT/mTOR cascades which alter therapy response. Oncotarget 3: 954-987, 2012.
4. Castellano E and Santos E: Functional specificity of RAS isoforms: So similar but so different. Genes Cancer 2: 216-231, 2011.
5. Prior IA, Lewis PD and Mattos C: A comprehensive survey of RAS mutations in cancer. Cancer Res 72: 2457-2467, 2012.
6. Fernandez-Medarde A and Santos E: RAS in cancer and developmental diseases. Genes Cancer 2: 344-358, 2011.
7. Pylayeva-Gupta Y, Grabocka E and Bar-Sagi D: RAS oncogenes: Weaving a tumorigenic web. Nat Rev Cancer 11: 761-774, 2011.
8. Forbes SA, Bindal N, Bamford S, Cole C, Kok CY, Beare D, Jia M, Shepherd R, Leung K, Menzies A, Teague JW, Campbell PJ, Stratton MR and Futreal PA: COSMIC: Mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res 39: D945-950, 2011.
9. Moura MM, Cavaco BM, Pinto AE and Leite V: High prevalence of RAS mutations in RET-negative sporadic medullary thyroid carcinomas. J Clin Endocrinol Metab 96: E863-868, 2011.
10. Buhrman G, O'Connor C, Zerbe B, Kearney BM, Napoleon R, Kovrigina EA, Vajda S, Kozakov D, Kovrigin EL and Mattos C: Analysis of binding site hot spots on the surface of RAS GTPase. J Mol Biol 413: 773-789, 2011.
11. Schulten HJ, Salama S, Al-Mansouri Z, Alotibi R, Al-Ghamdi K, Al-Hamour OA, Sayadi H, Al-Aradati H, Al-Johari A, Huwait E, Gari M, Al-Qahtani MH and Al-Maghrabi J: BRAF mutations in thyroid tumors from an ethnically diverse group. Hered Cancer Clin Pract 10: 10, 2012.
12. DeLellis RA and Williams ED: Thyroid and parathyroid tumors. In: Pathology and Genetics of Tumours of Endocrine Organs. IARC WHO Classification of Tumours. DeLellis RA, Lloyd RV, Heitz PU, and Eng C (eds.). Lyons, France: IARC Press, pp. 51-56, 2004.
13. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL and Trotti A (eds.). AJCC Cancer Staging Manual. 7th edition. New York, NY: Springer, pp. 87-96, 2010.
14. Schulten HJ, Al-Maghrabi J, Al-Ghamdi K, Salama S, Al-Muhayawi S, Chaudhary A, Hamour O, Abuzenadah A, Gari M and Al-Qahtani M: Mutational screening of RET, HRAS, KRAS, NRAS, BRAF, AKT1, and CTNNB1 in medullary thyroid carcinoma. Anticancer Res 31: 4179-4183, 2011.
15. McGinnis S and Madden TL: BLAST: At the core of a powerful and diverse set of sequence analysis tools. Nucleic Acids Res 32: W20-25, 2004.
16. Roy A, Kucukural A and Zhang Y: I-TASSER: a unified platform for automated protein structure and function prediction. Nat Protoc 5: 725-738, 2010.
17. DeLano W: The PyMOL Molecular Graphics System. DeLano Scientific, San Carlos, CA, USA. http://www.pymol.org. 2002.
18. Fukahori M, Yoshida A, Hayashi H, Yoshihara M, Matsukuma S, Sakuma Y, Koizume S, Okamoto N, Kondo T, Masuda M and Miyagi Y: The associations between RAS mutations and clinical characteristics in follicular thyroid tumors: New insights from a single center and a large patient cohort. Thyroid 22: 683-689, 2012.
19. Nikiforov YE: Molecular analysis of thyroid tumors. Mod Pathol 24(Suppl 2): S34-43, 2011.
20. Zhu Z, Gandhi M, Nikiforova MN, Fischer AH and Nikiforov YE: Molecular profile and clinical-pathologic features of the follicular variant of papillary thyroid carcinoma. An unusually high prevalence of RAS mutations. Am Clin Pathol 120: 71-77, 2003.
21. Buhrman G, Wink G and Mattos C: Transformation efficiency of RASQ61 mutants linked to structural features of the switch regions in the presence of RAF. Structure 15: 1618-1629, 2007.
22. Der CJ, Finkel T and Cooper GM: Biological and biochemical properties of human RASH genes mutated at codon 61. Cell 44: 167-176, 1986.
23. Di Cristofaro J, Marcy M, Vasko V, Sebag F, Fakhry N, Wynford-Thomas D and De Micco C: Molecular genetic study comparing follicular variant versus classic papillary thyroid carcinomas: Association of N-RAS mutation in codon 61 with follicular variant. Hum Pathol 37: 824-830, 2006.
24. Adeniran AJ, Zhu Z, Gandhi M, Steward DL, Fidler JP, Giordano TJ, Biddinger PW and Nikiforov YE: Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas. Am J Surg Pathol 30: 216-222, 2006.
25. Rivera M, Ricarte-Filho J, Knauf J, Shaha A, Tuttle M, Fagin JA and Ghossein RA: Molecular genotyping of papillary thyroid carcinoma follicular variant according to its histological subtypes (encapsulated vs. infiltrative) reveals distinct BRAF and RAS mutation patterns. Mod Pathol 23: 1191-1200, 2010.
26. Santarpia L, Myers JN, Sherman SI, Trimarchi F, Clayman GL and El-Naggar AK: Genetic alterations in the RAS/RAF/ mitogen-activated protein kinase and phosphatidylinositol 3- kinase/AKT signaling pathways in the follicular variant of papillary thyroid carcinoma. Cancer 116: 2974-2983, 2010.
27. Yu XM, Schneider DF, Leverson G, Chen H and Sippel RS: Follicular Variant of Papillary Thyroid Carcinoma is a Unique Clinical Entity: A Population-Based Study of 10,740 Cases. Thyroid 23: 1263-1268, 2013.
28. Garcia-Rostan G, Zhao H, Camp RL, Pollan M, Herrero A, Pardo J, Wu R, Carcangiu ML, Costa J and Tallini G: RAS mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer. J Clin Oncol 21: 3226-3235, 2003.
29. Liu J, Singh B, Tallini G, Carlson DL, Katabi N, Shaha A, Tuttle RM and Ghossein RA: Follicular variant of papillary thyroid carcinoma: A clinicopathologic study of a problematic entity. Cancer 107: 1255-1264, 2006.
30. Pinto AE, Silva G, Banito A, Leite V and Soares J: Aneuploidy and high S-phase as biomarkers of poor clinical outcome in poorly differentiated and anaplastic thyroid carcinoma. Oncol Rep 20: 913-919, 2008.
31. Ho AL, Grewal RK, Leboeuf R, Sherman EJ, Pfister DG, Deandreis D, Pentlow KS, Zanzonico PB, Haque S, Gavane S, Ghossein RA, Ricarte-Filho JC, Dominguez JM, Shen R, Tuttle RM, Larson SM and Fagin JA: Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. N Engl J Med 368: 623-632, 2013.
32. Sadow PM, Heinrich MC, Corless CL, Fletcher JA,\ and Nose V: Absence of BRAF, NRAS, KRAS, HRAS mutations, and RET /PTC gene rearrangements distinguishes dominant nodules in Hashimoto thyroiditis from papillary thyroid carcinomas. Endocr Pathol 21: 73-79, 2010.
33. Kang DY, Kim KH, Kim JM, Kim SH, Kim JY, Baik HW and Kim YS: High prevalence of RET, RAS, and ERK expression in Hashimoto's thyroiditis and in papillary thyroid carcinoma in the Korean population. Thyroid 17: 1031-1038, 2007.
34. Park KY, Koh JM, Kim YI, Park HJ, Gong G, Hong SJ and Ahn IM: Prevalences of Gs alpha, ras, p53 mutations and ret/PTC rearrangement in differentiated thyroid tumours in a Korean population. Clin Endocrinol 49: 317-323, 1998.
35. Liu RT, Hou CY, You HL, Huang CC, Hock L, Chou FF, Wang PW and Cheng JT: Selective occurrence of RAS mutations in benign and malignant thyroid follicular neoplasms in Taiwan. Thyroid 14: 616-621, 2004.
36. Ezzat S, Zheng L, Kolenda J, Safarian A, Freeman JL and Asa SL: Prevalence of activating RAS mutations in morphologically characterized thyroid nodules. Thyroid 6: 409-416, 1996.
37. Esapa CT, Johnson SJ, Kendall-Taylor P, Lennard TW and Harris PE: Prevalence of RAS mutations in thyroid neoplasia. Clin Endocrinol 50: 529-535, 1999.
38. Capella G, Matias-Guiu X, Ampudia X, de Leiva A, Perucho M and Prat J: RAS oncogene mutations in thyroid tumors: Polymerase chain reaction-restriction- fragment-length polymorphism analysis from paraffin-embedded tissues. Diagn Mol Pathol 5: 45-52, 1996.
39. Namba H, Rubin SA and Fagin JA: Point mutations of RAS oncogenes are an early event in thyroid tumorigenesis. Mol Endocrinol 4: 1474-1479, 1990.
40. Horie H, Yokogoshi Y, Tsuyuguchi M and Saito S: Point mutations of RAS and Gs alpha subunit genes in thyroid tumors. Jpn J Cancer Res 86: 737-742, 1995.
41. Vasko V, Ferrand M, Di Cristofaro J, Carayon P, Henry JF and de Micco C: Specific pattern of RAS oncogene mutations in follicular thyroid tumors. J Clin Endocrinol Metab 88: 2745-2752, 2003.
42. Riesco-Eizaguirre G and Santisteban P: New insights in thyroid follicular cell biology and its impact in thyroid cancer therapy. Endocr Relat Cancer 14: 957-977, 2007.